Raab & Moskowitz Asset Management LLC Sells 621 Shares of Johnson & Johnson (NYSE:JNJ)

Raab & Moskowitz Asset Management LLC reduced its holdings in shares of Johnson & Johnson (NYSE:JNJ) by 2.1% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 28,817 shares of the company’s stock after selling 621 shares during the period. Johnson & Johnson comprises about 1.1% of Raab & Moskowitz Asset Management LLC’s investment portfolio, making the stock its 23rd biggest position. Raab & Moskowitz Asset Management LLC’s holdings in Johnson & Johnson were worth $4,212,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in JNJ. Innealta Capital LLC bought a new position in Johnson & Johnson in the 2nd quarter valued at $27,000. MFA Wealth Advisors LLC acquired a new stake in shares of Johnson & Johnson in the second quarter valued at $43,000. Vermillion & White Wealth Management Group LLC bought a new position in shares of Johnson & Johnson in the fourth quarter valued at about $44,000. Fairfield Financial Advisors LTD acquired a new position in Johnson & Johnson during the 2nd quarter worth about $46,000. Finally, Grayhawk Investment Strategies Inc. grew its holdings in Johnson & Johnson by 528.6% during the 4th quarter. Grayhawk Investment Strategies Inc. now owns 308 shares of the company’s stock worth $48,000 after acquiring an additional 259 shares during the last quarter. Institutional investors own 69.55% of the company’s stock.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, VP Robert J. Decker sold 5,635 shares of the stock in a transaction on Friday, August 30th. The shares were sold at an average price of $165.06, for a total value of $930,113.10. Following the completion of the sale, the vice president now owns 18,973 shares in the company, valued at $3,131,683.38. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 0.16% of the stock is owned by company insiders.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on the stock. Daiwa Capital Markets lowered shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and reduced their target price for the stock from $160.00 to $150.00 in a research report on Tuesday, July 23rd. Daiwa America lowered Johnson & Johnson from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, July 23rd. Sanford C. Bernstein boosted their target price on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. TD Securities decreased their price target on Johnson & Johnson from $195.00 to $185.00 in a report on Thursday, July 18th. Finally, The Goldman Sachs Group dropped their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a report on Friday, July 19th. Seven investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Stock Down 0.0 %

NYSE:JNJ opened at $161.37 on Friday. The stock has a market cap of $388.37 billion, a price-to-earnings ratio of 10.06, a PEG ratio of 2.69 and a beta of 0.53. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The stock has a 50-day moving average price of $162.15 and a two-hundred day moving average price of $154.27. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Wednesday, July 17th. The company reported $2.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a return on equity of 36.60% and a net margin of 46.34%. The business had revenue of $22.45 billion during the quarter, compared to the consensus estimate of $22.33 billion. During the same period last year, the company earned $2.80 earnings per share. Johnson & Johnson’s quarterly revenue was up 4.3% on a year-over-year basis. As a group, equities analysts expect that Johnson & Johnson will post 10.02 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th were issued a $1.24 dividend. This represents a $4.96 annualized dividend and a dividend yield of 3.07%. The ex-dividend date was Tuesday, August 27th. Johnson & Johnson’s payout ratio is presently 30.92%.

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.